ADC Therapeutics SA (ADCT) stock
Close on Nov 11, 2026Market cap $204.27MP/E –Yield –
ADC Therapeutics SA grew revenue 12.8% to $84.87M over the twelve months to Sep 30, 2026. Free cash flow was -$100.55M. At the latest close the market valued the company at $204.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $204.27M
- P/E ratio
- –
- Price to sales
- 2.41
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -49.22%
Fundamentals
- Revenue
- $84.87M
- Net income
- -$81.25M
- EPS, diluted
- -$0.52
- Free cash flow
- -$100.55M
- Book value per share
- -$1.60
- Diluted shares
- 155M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $1.51
- Open
- $1.50
- Day's range
- $1.43 – $1.61
- Volume
- 769,034
- Average volume (20 days)
- 1,259,839
- Beta (5 years)
- 1.99
- 52-week range
- $0.78 – $4.98
- RSI (14 days)
- 53.8
- Volatility (1 year)
- 99.0%
- Relative volume
- 0.53×
- WACC
- 14.7%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADCT | S&P 500 | Difference | ADCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.5% | -2.4% | −5.1 pts | ||
| 3 months | +35.6% | -1.2% | +36.7 pts | ||
| Year to date | -54.7% | +12.3% | −67.0 pts | ||
| 1 year | -59.7% | +12.4% | −72.1 pts | ||
| 3 years | +240.4% | +78.8% | +161.6 pts | +50.4% | +21.4% |
| 5 years | -94.3% | +75.2% | −169.4 pts | -43.5% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ADC Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About ADC Therapeutics
Pharmaceutical Preparations
ADC Therapeutics is a commercial-stage biotechnology company focused on developing antibody drug conjugates to treat cancer. Its primary commercial product is ZYNLONTA, a CD19-directed therapy approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have received two or more lines of systemic treatment. The company also investigates expanded clinical applications for ZYNLONTA across earlier therapy lines and combinations, while advancing pipeline candidates such as ADCT-241 for prostate cancer. In the United States, it commercializes its medicine directly through pharmaceutical wholesale distributors that supply hospitals and oncology healthcare providers.
Company profile, executives and historyADC Therapeutics stock: common questions
What is ADC Therapeutics's stock price?
ADCT closed at $1.60 on Nov 11, 2026, up 5.96% on the day. Over the past 52 weeks it traded between $0.78 and $4.98.
What is ADC Therapeutics's market cap?
ADC Therapeutics was worth $204.27M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ADCT's P/E ratio?
ADC Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.52), so it has no meaningful P/E ratio.
How much revenue does ADC Therapeutics make?
ADC Therapeutics reported revenue of $84.87M for the twelve months to Sep 30, 2026, up 12.8% from a year earlier.
Does ADC Therapeutics pay a dividend?
No. ADC Therapeutics has not paid a cash dividend over the last twelve months.
When does ADC Therapeutics report earnings next?
ADC Therapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ADCT stock performed over the past year?
Including dividends, ADCT returned -59.7% over the past year, against +12.4% for the S&P 500.
How many ADCT shares are sold short?
6M shares were sold short at the latest FINRA report, 8.80% of the float, or 6.7 days of average trading volume.
Who are ADC Therapeutics's competitors?
Companies most similar to ADC Therapeutics by business, industry and size include KURA, RCUS, ZYME, VSTM, BCYC.
See a number that looks wrong?